
Voyager Therapeutics hasn’t yet disclosed which anti-amyloid antibody it’s vectorizing, only telling analysts that it’s been exploring “several options.” (Dr_Microbe/ Getty images)
Both presence of the same APOE4 gene variant that predisposes people to Alzheimer’s and the size of the initial dose have been linked to the development of ARIA. There is “biologic rationale” to suggest that gene therapy wouldn’t confer the same degree of risk, Voyager Chief Scientific Officer Todd Carter, Ph.D., said on the earnings call.
“In a gene therapy approach, the anti-amyloid antibodies are steadily secreted by cells in the central nervous system, and thus we’d be avoiding high antibody concentrations that necessarily follow intravenous antibody infusions,” he said. “Moreover, the antibody would first engage the beta amyloid deposited in and around beta amyloid plaques rather than around blood vessels, thus avoiding ARIA.”
Still, some risk does remain, Sandrock acknowledged on the call. The company is considering several mitigation strategies to handle ARIA if it does arise, including the use of a small molecule to control gene expression.
Voyager hasn’t yet disclosed which anti-amyloid antibody it’s vectorizing, instead telling an analyst on the call that the company has been exploring “several options.”
Source: https://www.fiercebiotech.com/research/voyager-therapeutics-adds-anti-amyloid-gene-therapy-alzheimers-pipeline

Check out our AAV CDMO service to expedite your gene therapy research
PackGene is a CRO & CDMO technology company that specializes in packaging recombinant adeno-associated virus (rAAV) vectors. Since its establishment in 2014, PackGene has been a leader in the AAV vector CRO service field, providing tens of thousands of custom batches of AAV samples to customers in over 20 countries. PackGene offers a one-stop CMC solution for the early development, pre-clinical development, clinical trials, and drug approval of rAAV vector drugs for cell and gene therapy (CGT) companies that is fast, cost-effective, high-quality, and scalable. Additionally, the company provides compliant services for the GMP-scale production of AAVs and plasmids for pharmaceutical companies, utilizing five technology platforms, including the π-Alpha™ 293 cell AAV high-yield platform and the π-Omega™ plasmid high-yield platform. PackGene’s mission is to make gene therapy affordable and accelerate the launch of innovative gene drugs. The company aims to simplify the challenging aspects of gene therapy development and industrialization processes and provide stable, efficient, and economical rAAV Fast Services to accelerate gene and cell therapy development efforts from discovery phase to commercialization.
Related News
Navega Therapeutics Receives $4 Million CIRM Grant to Advance Epigenetic Gene Therapy for Chronic Pain
SAN DIEGO, CA – February 4, 2025 – Navega Therapeutics, a pioneering biotechnology company developing cutting-edge epigenetic gene therapies, today announced a significant milestone with the receipt of a $4 million Translational Science grant from the California...
Akribion Therapeutics Secures €8 Million in Seed Financing to Advance Novel RNA-Guided Cell Depletion Technology
ZWINGENBERG, Germany, February 4, 2025 – Akribion Therapeutics, a biotechnology company pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announced the closing of an €8 million Seed financing round. The round was led by...
UF-Kure19 CAR-T Cell Therapy Demonstrates High CR Rates, Low Toxicity in R/R NHL
Treatment with UF-Kure19, a rapidly manufactured CAR T-cell therapy, led to complete responses (CR) and low toxicity in patients with relapsed/refractory non-Hodgkin lymphoma, according to data from a single-arm, mult-center phase 1 study (NCT05400109) presented at...
Opinion: Companies Vie to Develop a Hunter Syndrome Therapy That Reaches the Brain
Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio—have products in the pipeline that could improve treatment options for this rare disease. Hunter syndrome is a rare, X‐linked disease caused by a deficiency of the lysosomal enzyme...
Related Services

Plasmids GMP Services
Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.
READ MORE

AAV GMP Services
Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.
READ MORE

Technology Platforms
PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.
READ MORE